Introduction
Mitogenic stimulation of resting cells leads to both a general increase in net protein synthesis and preferential upregulation of cell cycle promoting proteins (Epifanova, 1977; Pardee et al., 1978; Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) . The general increase in protein synthesis is necessary to allow the cell to double its protein content and size before mitosis so that an average cell size is maintained during the physiologic proliferative response. When growth-stimulated cells are treated with protein synthesis inhibitors to decrease their protein synthesis by only 50% before the restriction point (R-point) in mid-late G1, they withdraw into the G0 resting state (Pardee et al., 1978; Zetterberg and Larsson, 1991; Zetterberg et al., 1995) . If protein synthesis is decreased after the R-point, the cell is able to complete one round of replication, but subsequently undergoes growth arrest. Normal cells are able to downregulate protein accumulation and withdraw into quiescence (G0) when growth factors are limiting (Hershko et al., 1971 ; for a review see Rosenwald, 1996b) . In contrast, as demonstrated in early studies, SV40-transformed cells, unlike normal cells, do not markedly decrease their macromolecular synthesis upon growth factor deprivation (Hershko et al., 1971) . It has been shown in polyoma virustransformed cells that one of the key mechanisms for the loss of control of protein synthesis is an inability to decrease ribosome number, which correlated with proliferation of transformed cells in fresh media without addition of serum growth factors (Stanners et al., 1979) . In this regard, it is appropriate to mention that during routine evaluation of biopsies, pathologists always pay special attention to the nucleoli (the sites where rRNA is synthesized and ribosomes assembled). In malignant neoplasms the nucleoli are altered in some way such as increased in number and/or in size. One example is illustrated in the Figure 1 , which depicts a malignant cell from a diffuse large B cell lymphoma. The cell contains a huge nucleoli comparable in size to erythrocyte (adhering to the cytoplasmic membrane of a neoplastic cell).
The association of altered nucleoli with neoplastic disorders was documented as early as 1933 (Haumeder, 1933 ; for detailed review and historical perspective see Koss, 1982) .
Although, this review cannot provide an extensive historical description of all the literature on the role of translational machinery in neoplastic transformation, some key discoveries are briefly summarized.
Translation factors are key players in growth control
The recently growing attention to the role of translational machinery in cell growth regulation and neoplastic transformation can be traced to discoveries in 1990, demonstrating that overexpression of translation initiation factor eIF-4E in NIH3T3 mouse fibroblasts allows them to quickly form colonies in soft agar and makes them highly tumorigenic in nude mice (Lazaris-Karatzas et al., 1990) . Overexpression of eIF-4E markedly amplifies the neoplastic charachteristics of human HeLa cells (De Benedetti and Rhoads, 1990) . It was later shown that antisense eIF-4E mRNA or expression of eIF-4E inhibitory proteins (4E-BPs) markedly decreases cap-dependent translation, proliferation rate and malignant properties of transformed cells (De Benedetti et al., 1991; Rousseau et al., 1996a; De Fatta et al., 2000 and references therein) . eIF-4E is the smallest subunit of the eIF-4F initiation complex (the other two subunits are eIF-4G and eIF-4A). eIF-4E (also known as capbinding protein) is considered to be a rate-limiting protein in translation initiation. It binds to the cap structure (m7GpppN, where m7 is a 7-methyl guanosine linked by a triphosphate bond to any nucleotide, N) present in eukaryotic mRNAs. eIF-4G is the largest subunit and has an eIF-4E binding site on its Nterminus, an eIF-3 binding segment (for the interaction with 40S ribosomal subunit) in its core domain, and eIF-4A binding segments both within the core domain and the C-terminus. eIF-4A is a helicase that is directed to the mRNA 5 0 end by the eIF-4F complex to unwind secondary structures that may impede scanning by the 40S ribosomal subunit. The initial binding of mRNA by eIF-4E is a key event in translation initiation as it allows mRNA transfer to the 40S ribosomal subunit for scanning after secondary structures in the 5 0 end are removed (Raught et al., 2000) . The discovery that eIF-4E overexpression transforms cells was interpreted in light of its biochemical role, and it was postulated that eIF-4E exerts transformation by increasing the translation of a subset of mRNAs encoding growth and transformation-involved proteins. Those mRNAs were predicted to have encumbered 5 0 untranslated regions (containing secondary structures), which make them particularly dependent on the eIF-4F complex for translation initiation (De Benedetti and Rhoads, 1990; Lazaris-Karatzas et al., 1990) . Soon, a number of studies revealed that eIF-4E specifically increases production of key growth-promoting proteins, including cyclin D1 (Rosenwald et al., 1993b (Rosenwald et al., , 1995 , ornithine decarboxylase (ODC; Shantz et al., 1996; Rousseau et al., 1996b) , and c-Myc (De Benedetti et al., 1994) . A direct link between eIF-4E-dependent translation and DNA replication has been established by demonstrating that eIF-4E specifically controls expression of ribonucleotide reductase (Abid et al., 1999) . Furthermore, eIF-4E increases production of fibroblast growth factor (FGF, Kevil et al., 1995) and vascular endothelial growth factor (VEGF, Kevil et al., 1996) , both of which play an essential role in angiogenesis. Finally, reduction of eIF-4E by antisense mRNA leads to decreased synthesis of collagenase type IV, an enzyme that plays a role in tumor invasion and metastasis (Graff et al., 1995) . For a detailed discussion of eIF-4E-induced increase in proteins associated with metastasis see the review by Graff and Zimmer (2003) . It has been shown that increased eIF-4E expression leads to activation of Ras function (Lazaris-Karatzas and , likely through an eIF-4E-mediated increase in the production of some autocrine growth factor (LazarisKaratzas and Rosenwald et al., 1995) . Although, the proteins listed above are preferentially regulated by eIF-4E, in most cases the mechanism of regulation has not been completely understood, and may involve complex and indirect regulation at both transcriptional and post-transcriptional levels (e.g. cyclin D1, see Rosenwald et al., 1993b Rosenwald et al., , 1995 Rousseau et al., 1996b) . For example, we have determined that eIF-4E becomes a rate-limiting factor for NF-kB production in serum-deprived NIH3T3 cells (Rosenwald, unpublished observation), which may explain the constitutive transcription of NF-kB-regulated genes (e.g. cyclin D1; Rosenwald et al., 1995) when eIF-4E overexpressing cells are deprived of growth factors (one recent publication describes a preferential dependence of NF-kB expression on eIF-4E in human colon adenocarcinoma cell line, Yang et al., 2003 ; only the abstract is available in English). It should be emphasized that eIF-4E also regulates the general translation rate, as expected from a general translation factor (De Benedetti et al., 1991; Rosenwald et al., 1999) . Therefore, whatever the mechanism by which eIF-4E regulates the preferential expression of particular proteins, the key point is that eIF-4E, like other general translation Figure 1 Cytospin preparation of a specimen submitted for flow cytometry from a patient with diffuse large B cell lymphoma (Wright stain). Note the huge nucleoli in the neoplastic cell (the nucleoli is about the size of an erythrocyte adhering to cell surface)
Role of translation in neoplastic transformation IB Rosenwald factors, is a key regulator of cell proliferation and other functions. To further extend this line of reasoning, studies on growth factor signaling revealed that all major growth signal transduction pathways are linked to activation of translational machinery, see Figure 2 . This field was reviewed before (Morris, 1995; Sonenberg, 1996; Raught et al., 2000) .
It should be noted that the signal transduction pathways illustrated in the Figure 2 also regulate other functions in the cell (transcription factors are also major targets of Ras-dependent pathways). For example, while Akt links to translational control, it also regulates the major transcription factor, NF-kB, which controls multiple genes involved in proliferative response (Romashkova and Makarov, 1999; Pahl, 1999) . Thus, a common theme that emerged from signal transduction studies is that any extracellular growth stimulus activates transduction pathways, leading not only to increased transcription but also to activation of translation.
Soon after the transforming potential of eIF-4E was discovered, another multisubunit translation initiation factor, eIF-2, was shown to be involved in neoplastic transformation when its function was upregulated. eIF-2 is composed of three subunits, a, b, and g, and is essential in translation initiation as it delivers initiator methionine tRNA (iMet-tRNA) to the 40S ribosomal subunit (Hinnebusch, 2000) . This step is carried out by a trimeric complex (eIF-2)-GTP-iMet-tRNA. The eIF-2b interacts with iMet-tRNA and ribosome-associated factor eIF-5. The eIF-2g plays a role in binding GTP and also contributes to interaction with iMet-tRNA. The eIF-2a subunit plays a key role in the regulation of eIF-2 activity. When (eIF-2)-GTP-iMet-tRNA binds to the ribosome, GTP hydrolysis occurs, resulting in a conformational change permitting transfer of iMettRNA to the ribosomal peptidyl site with simultaneous conversion of eIF-2-GTP to eIF-2-GDP. The later complex is relatively stable and must be recycled by eIF-2B to eIF-2-GTP before it can participate in the next round of iMet-tRNA transfer (Hinnebusch, 2000) . The interferon or double-stranded RNA-inducible protein kinase (PKR) regulates functional activity of eIF-2 complex by phosphorylating eIF-2a subunit (Wek, 1994) . When eIF-2a is phosphorylated the eIF-2-GDP complex binds eIF-2B very strongly and blocks GDP/GTP recycling, leading to inhibition of protein synthesis. Thus, the antiproliferative effect of interferon is explained to a large degree by PKR-mediated phosphorylation of eIF-2a (Wek, 1994) . It has been demonstrated that overexpression of mutant (nonfunctional) PKR in NIH3T3 abrogates the normal function of endogenous PKR (dominant-negative effect) and makes cells tumorigenic in nude mice (Koromilas et al., 1992) . The significance of eIF-2a phosphorylation is also indicated by findings that overexpression of mutant eIF2a, which cannot be phosphorylated, causes tumorigenic conversion of NIH3T3 cells (Donze et al., 1995) . Thus, an increase in the unphosphorylated/phosphorylated eIF-2a ratio facilitates protein synthesis, cell proliferation and neoplastic transformation. Also, other translation factors may contribute to neoplastic transformation when overexpressed. For example, both eIF-4G (Fukuchi-Shimogori et al., 1997) and p48 subunit of eIF-3 (Mayeur and Hershey, 2002) have been shown to transform NIH3T3 cells. Finally, the overexpression of elongation factor 1a predisposes BALB/c3T3 cells to carcinogen and UV-induced transformation (Tatsuka et al., 1992) .
Oncoproteins and tumor suppressor proteins activate or inhibit, respectively, components of translational machinery
The findings demonstrating that overexpression of eIF-4E exerts a tumorigenic effect (outlined above) were fascinating in that upregulation of translational machinery was implicated in causing neoplastic transformation. Among the questions a number of researchers set out to address was the possibility that expression and function of translation factors is increased as a result of oncogene activation (Rhoads, 1991) . It has been demonstrated that expression of activated Ras leads to an increase in the proportion of phosphorylated (active) eIF-4E (Rinker-Schaeffer et al., 1992; see Figure 2 outlining signal transduction pathways from Ras to translational machinery that were revealed in later studies). The increased expression of Src tyrosine kinase Figure 2 The major signal transduction pathways leading to activation of translational machinery. Note that not all major pathways are depicted in the figure. For example, the protein kinase C pathway (a major focus of the signal transduction field in the late 1980s and early 1990s) leads to phosphorylation and activation of eIF-4E (e.g. Tuazon et al., 1990) . Although not shown in this figure, it is also important to note that the mitogen-activated protein kinase (MAPK/ERK) cascade leads to activation of ribosomal RNA gene transcription by polymerase I (Zhao et al., 2003) and tRNA gene transcription by polymerase III (FeltonEdkins et al., 2003a, b) . All these findings clearly implicate major signal transduction pathways in activation of translation. Note that the signal transduction pathways described above are commonly discussed in terms of their central role in the regulation of pol IIdependent transcription of genes involved in cell cycle control (Hanahan and Weinberg, 2000) . The goal of this figure is to emphasize that translation is also a key target of regulation by all major signal transduction pathways. See also Raught et al. (2001) and Thomas (2002) for reviews on signal transduction and translational control also leads to phosphorylation of eIF-4E (Frederickson et al., 1991) . Another oncoprotein that is upregulated in a wide spectrum of human neoplasms (including lymphomas, colon and lung carcinomas), c-Myc, has been shown to activate transcription of both eIF-4E and eIF-2a genes and increase their expression at both RNA and protein levels in rodent fibroblast cell lines (Rosenwald et al., 1993a, b; Rosenwald, 1996a) and in a human B-lymphoblastoid cell line (Rosenwald, unpublished results) . c-Myc binds to specific sequences in eIF-4E and eIF-2a promoters implicating c-Myc as a transcription factor regulating these genes (Rosenwald et al., 1993a; Jones et al., 1996; Schmidt, 1999) . The oncoproteins known to increase c-Myc expression (Ras, Abl, Src) have also been shown to increase expression of both eIF-4E and eIF2a (Rosenwald, 1996a) . It should be noted that knocking out c-myc in fibroblast cells caused neither an appreciable decrease in eIF-4E nor in many other target genes earlier shown to be regulated by c-Myc (Bush et al., 1998) . It is likely that the importance of those genes is too high for a cell to tolerate their decrease, and alternative compensatory pathways allowed those genes to remain at high level of expression despite the loss of c-myc. c-Myc has been shown to increase expression of eIF-4E in hepatocytes (Kim et al., 2000) and B-lymphocytes (Rosenwald, unpublished data) , and have also been shown to increase expression of ribosomal protein genes (Kim et al., 2000) . It should be emphasized that c-Myc can both activate and repress transcription of many different genes. Among the genes that Myc activates are those encoding proteins involved in cell cycle progression, including cyclins and cyclindependent protein kinases and proteins necessary for DNA replication (Dang, 1999; Eisenman, 2001) . Of note, c-Myc has also been implicated in activation of tRNA genes by pol III as a result of its binding to the pol III transcription factor TFIIIB (Felton-Edkins et al., 2003b) . Not unexpectedly, new powerful techniques (SAGE and microarray analysis) have revealed that among the many genes induced by c-Myc, a significant portion encode proteins constituting translational machinery: eIF-4E, eIF-3, eIF-5A, eIF-4G, ribosomal proteins, nucleolar proteins, EF-2 and S6 kinase (Coller et al., 2000; Schuhmacher et al., 2001; Menssen and Hermeking, 2002) . Furthermore, the c-Myc homologue, N-Myc, has been shown in SAGE analysis to induce expression of 114 genes, the majority of which encode components of ribosome assembly and function (Boon et al., 2001) .
Other researchers concentrated on studying the role of key tumor suppressors (p53 and pRb) in regulating ribosomal RNA and tRNA production. It has been demonstrated that one of the functions of the retinoblastoma tumor suppressor gene product (pRB) and other pRB family members (e.g. p130) is to downregulate the activity of RNA polymerase I (pol I), which leads to decreased ribosomal RNA (rRNA) gene transcription. pRb interferes with the function of upstream binding factor (UBF) necessary for pol I function (Cavanaugh et al., 1995; Voit et al., 1997; Ciarmatori et al., 2001) . Human papillomavirus E7 protein (known to be implicated in cervical carcinoma development; Munger et al., 1992) binds and inactivates pRB, which correlates with abrogation of the inhibitory effect of pRb on rDNA transcription (Cavanaugh et al., 1995) . Furthermore, pRB represses transcription of RNA polymerase III-dependent genes (including tRNA genes). Cells lacking functional pRB have elevated levels of pol III activity Larminie et al., 1998) . Thus, a loss of pRB function leads to increased rRNA and tRNA production facilitating protein synthesis and accelerated cell proliferation (depicted in Figure 3 ). Remarkably, it turned out that p53 in addition to its other roles in the cell suppresses ribosomal and tRNA gene transcription. In the case of rRNA genes, p53 represses their transcription through interaction with yet unidentified factor, as demonstrated in cells lacking or overexpressing p53 (Budde and Grummt, 1999) . This correlates well with increased pre-rRNA levels observed in cells expressing mutant p53 or in cells from p53 knockout mice (Budde and Grummt, 1999) . The inhibition of tRNA gene transcription by pol III is due to an interaction of p53 with the TFIIIB transcription factor (Crighton et al., 2003 and references therein) . In relation to the findings outlined above it should be mentioned that the tumor suppressor protein Arf has been shown to inhibit rRNA production and processing (Sugimoto et al., 2003) . For an extensive review on the regulation of pol I and pol III see the article by Robert J White in this issue. It should be noted that p53, and likely pRb as well, may exert inhibitory effects on the translational machinery in many ways. For example, p53 activation results in dephosphorylation of 4E-BP1, inhibition of ribosomal protein S6 kinase, and inhibition of translation, although the mechanism linking p53 to signal transduction pathway(s) remains to be elucidated (Horton et al., 2002) .
Another tumor suppressor that is inactivated in a wide spectrum of human neoplasms is Phosphatase and Tensin Homologue (PTEN), which is a dual-specificity phosphatase that has activity toward both phosphorylated peptides and phospholipids. PTEN inhibits activation of Akt, the downstream effector of PI3-kinase, which is integral to cell proliferation, migration, survival, and angiogenesis. Since signaling downstream from Akt is linked to a number of translation factors (see Figure 2 ) and to ribosome biogenesis through transcription of ribosomal protein genes (see Ruggero and Pandolfi, 2003 for a review and references), it is evident that inactivation of PTEN leads to increased production and function of various components of the translational machinery.
Complexity of the networks regulating components of translational machinery and of the effects of translation factors on gene expression This section will address the example of complex interactions of c-myc, eIF-4E, and cyclin D1. The regulation of cyclin D1 expression can occur at many levels, including transcription (Albanese et al., 1995; Hinz et al., 1999) , nucleo-cytoplasmic transport of its mRNA (Rousseau et al., 1996b) , and post-transcriptional levels not completely defined (Hashemolhosseini et al., 1998; Muise-Helmericks et al., 1998; Brewer et al., 1999) . It is likely that cyclin D1 mRNA and protein stability also contribute to the regulation (Hashemolhosseini et al., 1998) . Whether expression of cyclin D1 is regulated at a step that can be strictly defined as translation (after mRNA is delivered to the cytoplasm and until peptide product is released from the ribosome) has not been determined.
Expression of cyclin D1 can be induced independently either through PI3K (NIH3T3 cells; Takuwa et al., 1999) or RAS/ERK (established Chinese hamster lung fibroblasts CCL39; Lavoie et al., 1996) pathways (see Figure 2 outlining these pathways). The relative contribution of transcriptional and post-transcriptional points of regulation has not been determined. Nevertheless, in the human colon carcinoma Colo205 cell line post-transcriptional regulation (independent of total cyclin D1 mRNA levels) in response to serum stimulation through the PI3K/AKT-dependent pathway has been demonstrated (Muise-Helmericks et al., 1998). Moreover, this regulation is both PI3K and FRAP/ TOR-dependent, but inhibition of RAS, Raf, and MEK failed to affect cyclin D1 induction. The post-transcriptional control of cyclin D1 also takes place during the endoplasmic reticulum stress response in NIH3T3 cells (Brewer et al., 1999) . These findings indicate that: (a) different signal transduction pathways are involved in the regulation of cyclin D1; (b) the regulation can take place at both transcriptional and post-transcriptional levels; and (c) the preferential levels of regulation and the pathways involved may differ depending on extracellular signals and on the cell type.
As noted above, eIF-4E positively regulates expression of cyclin D1 (Rosenwald et al., 1993b (Rosenwald et al., , 1995 . It is likely that eIF-4E is one of the key factors determining the levels of cyclin D1 protein in various cell types. This is due to the fact that eIF-4E itself is activated through a Ras/Raf/MEK/ERK/MNK1-dependent pathway (see Figure 2 and references therein). Importantly, activation of eIF-4E as a consequence of its dissociation from 4E-BPs is achieved by phosphorylation of 4E-BPs induced through PI3K/Akt/FRAP/mTOR-dependent pathway (see Figure 2 ). As mentioned above, different cell types and different signals may rely preferentially on one or another pathway, either of which would lead to activation of eIF-4E function.
The mechanism by which eIF-4E elicits its effect on cyclin D1 expression is no less complex than the upstream mechanisms leading to activation of eIF-4E function. For example, when NIH3T3 cells are grown in the presence of serum, cyclin D1 mRNA levels are not markedly increased in eIF-4E overexpressing cells, while its protein levels increase disproportionately to changes at mRNA level, indicating that post-transcriptional regulation is involved (Rosenwald et al., 1993b) . However, when cells are deprived of serum, the marked differences in cyclin D1 mRNA levels are revealed: the eIF-4E-overexpressing cells continue to express cyclin D1 mRNA at high levels, but control cells do not display detectable cyclin D1 mRNA (Rosenwald et al., 1995) . We determined that eIF-4E overexpressing cells maintained high rates of cyclin D1 gene transcription even when deprived of serum (nuclear run-on assay), but control cells markedly attenuated its transcription (Rosenwald et al., 1995) . We explain these observations by postulating that under serum deprivation conditions, eIF-4E is a rate-limiting translation factor for the synthesis of a transcription factor acting on the promoter of cyclin D1 gene. One promising candidate Figure 3 Activation of translational machinery as a common pathway initiating and promoting neoplastic transformation. Aberrant increases in oncoprotein expression and function lead to oncoprotein-induced increases in the expression and function of the translational machinery (eIF-4E and eIF-2 shown as examples, but it should be emphasized that many other components of translational machinery are activated in terms of their expression and function, see text for examples and references). Preferential eIF-4E-dependent increase in cyclin D1 expression and CDK-4 activation would lead to hyperphosphorylation and inactivation of pRB, thus removing the repressing effect of pRB on pol I and pol III function. Inactivation of pRB and p53, which takes place in many tumors would independently lead to activation of pol I and pol III function. Increased expression and function of the translational machinery leads to accelerated synthesis of all cellular proteins, including those directly involved in cell proliferation. Accelerated protein synthesis puts pressure on the cell to replicate as continuous protein accumulation in the absence of cell replication results in unbalanced growth and cell death (Rueckert and Mueller, 1960 ). An important outcome of constitutive increase in translation is that there will be both general increase in protein synthesis and preferential increases in production of growthpromoting proteins (e.g. members of the cyclin family, growth factors, signal transduction molecules, see text above). This would lead to constitutive positive feedback (vicious circle) maintaining the activated state of translational machinery. Although not shown in this figure, the activation of CDK-4 by cyclin D1 causes phosphorylation of the UBF transcription factor, which increases pol I-dependent transcription of rRNA genes (Voit et al., 1999) ; furthermore, CDKs have been demonstrated to govern formation and maintenance of the nucleolus (Sirri et al., 2002) . While this figure concentrates on the role of major cell cycle regulators in the control of the translational machinery, it must be emphasized that release of E2F transcription factor as a result of pRb inactivation leads to transcription of genes encoding proteins directly involved in cell replication (Sherr, 1996) . Thus, effects on translational machinery take place simultaneously with the transcriptional effects on genes directly involved in cell proliferation is NF-kB, which has binding sites within the cyclin D1 promoter and is known to positively regulate transcription of this gene (Hinz et al., 1999) . We have found that NIH3T3 cells overexpressing eIF-4E do not decrease NF-kB protein levels when deprived of serum (Rosenwald, unpublished data) . In any case, whether the effect of eIF-4E on NF-kB is direct or indirect, the example of transcriptional regulation of cyclin D1 by eIF-4E illustrates that eIF-4E can achieve its downstream effects through regulation of transcription factors.
The post-transcriptional effect of eIF-4E on cyclin D1 expression clearly seen when cells are cultured in the presence of serum (Rosenwald et al., 1993b) , is at least in part connected with eIF-4E-facilitated nucleo-cytoplasmic transport of cyclin D1 mRNA (Rousseau et al., 1996b) . Again, whether this nucleo-cytoplasmic transport directly depends on eIF-4E binding to cyclin D1 mRNA, or is mediated by induction of some transporter protein by eIF-4E, remains to be determined.
As outlined above, there are different signal transduction pathways leading to increased eIF-4E function. In addition, the same regulatory protein usually increasing eIF-4E gene expression may not always do so. An example is c-Myc. While there are a number of independent reports documenting the role of c-Myc in inducing eIF-4E gene expression (see previous sections), in one publication there was no marked decrease in eIF-4E expression as a result of c-myc knockout (Bush et al., 1998) . Our interpretation of this finding is that a c-Mycindependent pathway became operative during selection of these c-myc null cells in order to prevent deleterious consequences of c-Myc loss. These results point to a possibility that eIF-4E gene transcription may be regulated by c-Myc-independent pathway(s).
Interestingly, even in the cell culture models where c-Myc induces eIF-4E expression and one would expect that eIF-4E induction by c-Myc should lead to increased cyclin D1 expression, the situation is not as simple. For example, it has been shown that activation of c-Myc function in serum-deprived Rat-1 fibroblasts induces cyclin D1 mRNA increase by a transcriptional mechanism (Daksis et al., 1994) , which is likely explained by the presence of c-Myc binding sites in cyclin D1 promoter (Peukert et al., 1997) . However, increased c-Myc function in serum-deprived BALB/c3T3 cells does not have any effect on cyclin D1 mRNA (Jansen-Durr et al., 1993; Rosenwald et al., 1993b) , but leads to increases in cyclin D1 protein, suggesting a post-transcriptional eIF-4E-dependent mechanism (Rosenwald et al., 1993b) . However, when BALB/c3T3 cells are cultured in the presence of serum, increases in c-Myc activity downregulate cyclin D1 mRNA and protein levels (JansenDurr et al., 1993) . The effect of c-Myc on eIF-4E expression in BALB/c3T3 cells under those conditions (presence of serum) has not been tested. Noteworthy, overexpression of c-Myc in primary rat embryo fibroblasts (REF-myc cells), grown in the presence of serum, leads to increase in eIF-4E at protein level (Rosenwald, 1996a) , but at the same time the cyclin D1 expression becomes barely detectable (Rosenwald, unpublished results; Tan et al., 2000) . Interestingly, enforced additional expression of eIF-4E from exogenous vector restores cyclin D1 expression in REF-myc cells . These findings point to a complexity of interactions between c-myc, eIF-4E, and cyclin D1. Depending on the cell context (Myc-interacting proteins, other modulators, presence or absence of serum growth factors in cell culture media), c-Myc can stimulate or inhibit cyclin D1 protein expression, and the level of eIF-4E may be critical in determining the outcome. Further studies addressing all possible levels of regulation should be performed in several cell culture models to comprehensively understand the complexity of interactions between the three genes discussed above.
The role of translation factors in protection from apoptosis
Attenuation of apoptosis plays a role in neoplastic transformation. Increased expression and function of certain translation factors markedly suppresses the rate of apoptosis. It has been demonstrated that ectopic overexpression of eIF-4E completely blocks apoptosis when cells are deprived from serum growth factors. Importantly, c-Myc-induced apoptosis is also blocked in eIF-4E-overexpressing cells (see Polunovsky et al., 1996; Rosenwald 1996b) . It has been further demonstrated that eIF-4E-dependent increase in cyclin D1 is important for the anti-apoptotic effect of eIF-4E , and that eIF-4E is a key mediator of an antiapoptotic function of Ras . It should be noted that the functional activities of other translation factors (eIF-4F, eIF-2, elongation factor 1a) have been shown to be important for protection from apoptosis (Clemens, 2001; Morley, 2001; Thornton et al., 2003) .
Translational machinery and human neoplasms
The literature discussed in the previous sections is based on experiments with cultured cells. In this section I will review only a portion of the fast growing literature on the components of translational machinery in human neoplasms (the search of pubmed on 3 March 2004 using keywords: 'translation factor and human cancer' yielded 708 references, 500 of them since June 1995). The focus of this section will be on translation factors, and most of the cited literature (with some exceptions) will be related to the expression of translation factors in actual human neoplasms rather than in cultured cells. The goal of this section will be to emphasize the relevance of molecular studies obtained in cultured cells to human neoplasms and to evaluate the findings that raise intriguing questions providing the basis for future research.
As a reference information, the statistics for the estimated new cancer cases and cancer deaths in US for the year 2003 (top nine) is presented in Table 1 (based on the data from Jemal et al., 2003) .
Breast cancer
An early report described expression of eIF-4E based on immunohistochemical (IHC) studies and Western blots applied to human biopsies (Kerekatte et al., 1995) . The authors concluded that eIF-4E was increased in breast carcinomas. The quantitative analysis of 38 breast carcinoma biopsies based on Western blot studies showed that eIF-4E was elevated three-to 10-fold. Another study of 112 breast cancer samples from the same group demonstrated a three-to 30-fold increase in eIF-4E using the same Western blot strategy . In a prospective study of 191 patients using a similar approach for eIF-4E quantitation, the authors concluded that the risk of breast cancer-related death is markedly higher in patients whose biopsies demonstrate more pronounced upregulation of eIF-4E based on Western blot studies (Li et al., 2002) . Our IHC analysis does not support the results sited above (unpublished results). We analysed 10 specimens including carcinoma in situ and invasive carcinomas. In half of the specimens we did not find any appreciable increase in eIF-4E expression when normal ductal epithelium was evaluated in the same biopsies (usually in the same microscopic field) with the neoplastic component. We consider it essential to do such comparison in IHC studies because there is significant variability during processing, fixation, embedding, antigen retrieval, and actual IHC staining between specimens, and even between areas of the biopsy on one slide. Also, differences in the time of storage between specimens can affect results. It does not appear that in the publications discussed above eIF-4E expression was evaluated in neoplastic and benign components next to each other (ideally in one microscopic field). Next, quantitation based on Western blot studies is not reliable for the following reasons. First, tumor samples always contain various cellular populations, including neoplastic cells, stromal cells, and dead cells. We have emphasized earlier (Rosenwald et al., , 2001a ) that stroma, which has lower eIF-4E levels than epithelial component, may contribute variably to protein extracts prepared from resected tumors and benign controls, making it difficult to be certain that results are not misinterpreted due to significant contribution of stromal elements. Second, in the case of breast carcinomas, the tumor bulk of the biopsy is highly variable between biopsies, some being more and some less cellular. Consequently, the results discussed above can be explained by that control tissues contained little eIF-4E (minimal normal epithelial component), while breast cancer biopsies (as compared to controls) had more eIF-4E due to a larger epithelial component (derived from tumor). It is likely that the correlation of poor prognosis with the magnitude of eIF-4E increase (discussed above) was due not to increased eIF-4E in tumor cells, but to the increased presence of the epithelial component in the biopsies (more invasive tumors). Therefore, we believe that careful selection of cases for IHC studies, where both tumors and normal tissues of tumor origin can be found in close proximity, is a more reliable way to evaluate increased protein expression in the tumor biopsies. The evaluation assisted by laser capture microdissection can generate quantitative results. Regarding results of eIF-4E expression in breast cancer, it is likely that there is no increase of this initiation factor in a significant portion of cases and a dedicated study is necessary to provide statistically reliable IHC results. With respect to other translation factors, amplification of a gene encoding the p40 subunit of eIF-3 has been detected in some breast carcinomas (Nupponen et al., 1999) .
Colon cancer
Our IHC analysis of colonic adenocarcinomas revealed that eIF-4E is markedly increased in tumor cells (in 34 out of 34 cases analysed) as compared to normal epithelium where its expression is only detectable in the bottom of the crypts (normal proliferative zones, Figure 4 , Rosenwald et al., 1999) . Even when expression of eIF-4E in tumor cells is compared to its expression in proliferative areas of normal colonic epithelium (crypts), the expression of eIF-4E is much higher in tumor cells (compare intensity of a brown color in the tumor Figure 4 , top left and in the normal colonic glands at the crypt level, Figure 4 , top right). Importantly, increase in Role of translation in neoplastic transformation IB Rosenwald eIF-4E expression always takes place early in colon tumor progression as its levels are already increased at the adenoma stage (total 36 cases analysed; Figure 4 , bottom left: note a sharp transition from normal epithelium to adenoma marked by striking upregulation of eIF-4E; Rosenwald et al., 1999) . Our findings have been confirmed by other investigators (Berkel et al., 2001) . The results on expression of eIF-2a are the same: this factor is always increased in both adenomas and carcinomas (22 adenomas and 25 carcinomas were analysed; Rosenwald et al., 2003) . Importantly, we observed that non-neoplastic epithelium close to the carcinoma areas frequently displayed higher levels of both eIF-4E and eIF-2a than normal epithelium away from tumor, suggesting that paracrine/autocrine growth factors are produced by carcinomas (Figure 4 , bottom right). We have not observed this phenomenon in adenoma cases.
Two major regulatory pathways converging on c-Myc are likely to regulate eIF-4E and eIF-2a expression in colonic epithelium Apc-dependent pathway Normal adenomatous polyposis coli protein (APC) interacts with a number of proteins, including b-catenin, axin, and GSK-3b kinase.
Binding of b-catenin to APC is essential as it allows GSK-3b (apparently docked to axin) to phosphorylate b-catenin. The phosphorylation of b-catenin is a key regulatory step as it marks this protein for ubiquitinmediated degradation (Polakis, 2001) . APC is mutated in the majority of hereditary and sporadic colorectal cancers (Kinzler and Vogelstein, 1996; Polakis, 1999) . Importantly, APC is mutated and inactivated at an adenoma stage in the colon tumor progression sequence (Kinzler and Vogelstein, 1996; Lamlum et al., 2000) . The majority of these mutations truncate the protein and alter its ability to bind b-catenin, thus precluding bcatenin phosphorylation by GSK-3b (Polakis, 1999 (Polakis, , 2001 ). This results in accumulation of b-catenin that forms complexes with Tcf transcription factors (Tcf1, Tcf3, and Tcf4) in the nucleus leading to activation of target genes (Eastman and Grosschedl, 1999; Roose and Clevers, 1999; Hovanes et al., 2001) . It has been shown that c-myc expression is transcriptionally activated as a result of binding of b-catenin/Tcf4 complexes to Tcfresponse elements in the c-myc promoter (He et al., 1998) . These results, taken together with: (1) our earlier findings on transcriptional activation of eIF-4E and eIF2a gene expression by c-Myc in cultured fibroblast models (Rosenwald et al., 1993a, b; Rosenwald, 1996a, b) ; (2) increased c-Myc expression in colonic adenomas and carcinomas (Melhem et al., 1992) ; and (3) our findings that both eIF-4E and eIF-2a expression is upregulated in colonic adenomas and carcinomas (Rosenwald et al., , 2003 , make it very likely that eIF-4E and eIF-2a are among the downstream target genes regulated by the APC-dependent pathway. An investigation on the potential role of eIF-4E and eIF-2a as a downstream target genes regulated by APCdependent pathway in colonic epithelial cells is essential in order to show a link between the tumor suppressor APC and the translational machinery. It should be noted, however, that other links between the APC and translational machinery are likely to exist as well. For example, it is known that GSK-3b phosphorylates eIF-2B (the GTP exchange factor for eIF-2) in the colon carcinoma cell line HT-29 (Tuhackova et al., 1999) . It is known that phosphorylation of eIF-2B by GSK-3b is inhibitory (Welsh et al., 1998) . As outlined above, GSK-3b is docked on APC, and this makes it possible that downregulation of eIF-2B by GSK-3b is somehow dependent on normal APC function.
TGFb-dependent pathway The TGFb proteins trigger signaling through receptor complexes that phosphorylate Smad transcription factors (Polyak 1996; Massague et al., 2000; Massague, 2000; Markowitz, 2000) . The TGFb ligand binding allows dimerization of type I and type II TGFb receptors (TGFbRI and RII, both of which are serine/threonine kinases). The type II receptor activates TGFbRI that propagates signaling by phosphorylating Smads. The Smads interact with various proteins to regulate expression of target genes in the nucleus. The mechanism of TGFb-induced growth arrest is tightly linked to c-Myc regulation. The treatment of responsive cells by TGFb leads to rapid transcriptional suppression of c-myc gene expression. The downregulation of c-Myc is necessary for growth arrest because enforced expression of c-Myc abrogates the growth inhibitory effect of TGFb (Mulder and Brattain 1988; Mulder et al., 1990; Pietenpol et al 1990; Alexandrow and Moses 1995) . Further, TGFb causes inhibition of cyclin-dependent kinase (CDK) complexes (Koff et al., 1993) through induction of CDK inhibitory proteins (Sherr and Roberts, 1999; Massague, 2000; Staller et al., 2001; Seoane et al., 2001 ). It appears that induction of CDK inhibitor p15 is necessary for TGFbinduced growth arrest of epithelial cells and that induction of p15 depends on downregulation of c-Myc (Warner et al., 1999) . Thus, multiple events would explain the role of c-Myc downregulation: inhibition of CDKs due to accumulation of CDK inhibitory proteins and downregulation of a number of growth promoting genes, including eIF-4E and eIF-2a.
Different mechanisms are responsible for the loss of TGFb signal transduction during colon tumor progression: decreased expression of TGFb receptor I, mutations in the TGFb receptor II, loss of DPC4 (encoding TGFb signal transducer Smad4) and mutations in Smad2 (Markowitz et al., 1995; Wang et al., 1996; Markowitz, 2000) . Therefore, it will be important to establish a link between the TGFb-dependent pathway and translational control through regulation of the cMyc target genes eIF-4E and eIF-2a in colonic epithelial cells. A working hypothesis summarizing the discussion above is presented below. and Vogelstein, 1996) . In contrast, it has been found that mutations in the TGFb type II receptor frequently occur during the transition from an adenoma (benign lesion) to a carcinoma (Grady et al., 1998) . This may explain in part the observation that carcinomas commonly have a more pronounced increase in c-Myc expression than adenomas (Melhem et al., 1992) . Accordingly, eIF-4E appears to be more strongly expressed in colonic carcinomas than in adenomas (Berkel et al., 2001 ). The simultaneous inactivation of APC and Smad4 in mice potentiates intestinal tumor growth pointing to the possibility that sequential mutations in the APC and TGFb systems may collaborate during tumor progression (Takaku et al., 1998) . Thus, it will be important to determine whether simultaneous inactivation of both the TGFb and APC-dependent pathways has a more pronounced effect on c-Myc upregulation and on its potential targets, eIF-4E and eIF-2a, as well as other components of translational machinery, than inactivation of each of these pathways alone.
Possible Myc-independent regulation of eIF-4E in colonic cells We have searched human eIF-4E promoter sequence for possible Tcf-binding sites. Two segments of interest were found. One site, CCTTTGGTT, at position -969 is very close to a TBE1 site, which binds Tcf4 (He et al., 1998) , and contains a G instead of an A in the last triplet. Another segment, GACAAAG at position -366 is close to Tcf1-binding site (Roose and Clevers, 1999) and contains a G instead of an A at the first position. Therefore, it is possible that the APCdependent pathway may regulate eIF-4E promoter both through Myc-dependent and independent mechanisms in colonic epithelial cells.
Note that in the colon cancer section I have focused on the discussion of likely eIF-4E and eIF-2a regulation by Myc. However, Myc activates expression of many other components of the translational machinery (as described in previous sections), suggesting they are potential targets of APC-and TGFb-dependent pathways as well. All of these possibilities deserve further investigation to determine which components of the translational machinery are altered and what mechanisms are responsible for these alterations. Finally, it should be emphasized that whatever translational components are upregulated at the adenoma stage, their elevated expression is not sufficient to induce a fully malignant phenotype, and many other changes take place before an adenoma gives rise to a carcinoma.
Lung cancer
An extensive analysis of the translational machinery in various types of lung carcinomas is lacking. It has been demonstrated in one study that eIF-4E appears to be increased in adenocarcinomas of peripheral lung, including bronchioloalveolar carcinomas and mixed adenocarcinomas with both bronchioloalveolar and papillary patterns. Based on the Western blot results, the authors suggested a correlation between the magnitude of the eIF-4E increase and the invasiveness of the tumors (Seki et al., 2002) . The correlation with invasiveness (based on Western blot results) likely reflects the larger portion of protein extracted from the tumor rather than the stroma, and therefore may not be a reflection of increased eIF-4E (discussed in breast cancer section). In our IHC study, we have found that both eIF-4E and eIF-2a are commonly increased in bronchioloalveolar carcinoma cells when compared to normal epithelium of the alveolar walls and bronchi, Figure 5 (total 22 cases analysed; Rosenwald et al., 2001a) . However, unexpectedly, both translation initiation factors were not increased in most of the squamous cell carcinoma cases. In fact, eIF-4E was either undetectable or barely identifiable in 17 out of 19 cases; results for eIF-2a were the same in 15 out of 19 cases (note that the internal control for both factors confirmed adequate methodological procedures, see Figure 5 legend).
Squamous cell carcinomas are characterized by high proliferation rates (note that nearly 100% of tumor cells express cyclin D1, however, the same tumor is negative for both eIF-4E and eIF-2a, Figure 5 ). Therefore, an increase in the protein synthesis rate must take place in the tumor cells. Several explanations for the lack of eIF-4E and eIF-2a reactivity may be suggested: (a) the factors are expressed at very low levels not detectable by IHC; (b) the factors are not expressed due to deletions; (c) the immunoreactive epitops recognized by the monoclonal antibodies we used are mutated, making the proteins undetectable. The last possibility seems to be less likely as the same epitope would have to be altered in most of the cases that we studied. However, if this turns out to be the case, then some type of a recurrent abnormality in both eIF-4E and eIF-2a should be readily identifiable. I currently favor the possibilities (a) and/or (b). In such a case one would expect that an alternative mechanism must exist for increasing protein synthesis, bypassing the need for eIF-4E and eIF-2a.
Interestingly, it has been shown that eIF-4G is overexpressed as a result of gene amplification in some cases of squamous cell carcinoma (Bauer et al., 2002) . The overexpression of eIF-4G may be one of the mechanisms bypassing requirement for eIF-4E since this factor has been shown to facilitate cap-dependent translation even if it lacks eIF-4E-binding site (Ali et al., 2001) . With regard to eIF-2a, it should be mentioned that this is a regulatory subunit of eIF-2, the phosphorylation of which leads to inactivation of the complex. Thus, selective pressure during tumor progression may lead to elimination of eIF-2a altogether or to a markedly decreased expression of this factor that make it unable to decrease eIF-2 activity upon eIF-2a phosphorylation (see further discussion below).
Another interesting observation deserves mentioning. It has been shown that c-Myc is highly expressed in about 50% of squamous cell carcinomas (Volm et al., 1992) . Taken together with our findings that most of these tumors do not show any increase in either eIF-4E or eIF-2a, it follows that c-Myc does not always induce expression of usual downstream targets, probably because of tissue or tumor-specific context (or to target gene mutations).
Other nonhematopoietic tumors
It should be noted that other neoplasms have altered expression of translational factors or other components of the translational machinery. In prostate carcinomas, the amplification of the eIF-3S3 gene (Saramaki et al., 2001 ) and the expression of a truncated variant of translation elongation factor 1a (Sun et al., 1997) has been reported. Also, amplification and overexpression of a gene coding for the p40 subunit of eIF-3 has been detected in prostate carcinomas (Nupponen et al., 1999 ). An increased eIF-4E mRNA level was noted in transitional urine bladder carcinomas (although protein levels were not determined, and careful IHC study was not presented; Crew et al., 2000) . The expression of eIF-4E appears to be increased in head and neck carcinomas, which correlates with progressive eIF-4E gene amplification (Nathan et al., 1997; Sorrells et al., 1999) . The ribosomal protein L15 gene appears to be overexpressed in esophageal cancer . Amplification of the S6 kinase gene has been identified in a subset of anaplastic meningiomas (Cai et al., 2001) . Thyroid carcinomas display increased expression of eIF-4E and eIF-2a, which appears to correlate with aggressiveness of the tumors (Wang et al., 2001b) . Expression of eIF-2a is increased in both benign melanocytic nevi and malignant melanomas (total six nevi and nine melanomas analysed; Rosenwald et al., 2003) . Interestingly, eIF-4E is weekly expressed or undetectable in both benign melanocytic nevi and melanomas, despite the fact that melanomas are very fast growing aggressive malignant neoplasms (Rosenwald et al., 2003) .
Lymphomas
We have analysed by immunohistochemistry the expression of eIF-4E and eIF-2a in a series of cases representing major types of non-Hodgkin's lymphomas . As a control we used non-neoplastic lymph nodes containing reactive germinal centers (mostly antigen-activated B cells) and mantle and paracortical area (containing mostly non-activated B and T-cells, respectively). We have found that normal germinal center cells (areas where activated B cells proliferate before differentiating and relocating to other areas within the lymphoid system to become antibodysecreting plasma cells) display high levels of both eIF-4E and eIF-2a, while nonproliferating B and T cells have barely detectable or undetectable expression . All types of non-Hodgkin's lymphoma cases analysed in this study showed increased eIF-4E and eIF-2a as compared to small nonactivated lymphocytes, and the degree of increase appeared to correlate with the lymphoma grade. We have determined that c-Myc induces expression of eIF-4E in a human lymphoblastoid cell line (Rosenwald, unpublished data) . Since c-Myc is upregulated not only in Burkitt lymphoma (this lymphoma is characterized by translocation of c-myc to one of the actively transcribed immunoglobulin gene loci) but also in other non-Hodgkin's lymphomas (due to other mechanisms of upregulation, SanchezBeato et al., 2003) , it is likely that upregulation of c-Myc contributes to increased eIF-4E and eIF-2a expression in various types of non-Hodgkin's lymphomas.
The findings regarding upregulation of eIF-4E and eIF-2a in lymphomas are not surprising. However, during Western blot analysis of some lymph nodes effaced by lymphomas we came across an unexpected result. One of the cases of diffuse large B cell lymphoma (for which frozen tissue was available, but paraffin block was not present for IHC analysis) demonstrated neither detectable eIF-4E nor eIF-2a expression at the protein level ( Figure 6 ). First, we suspected that failure to load protein on the lane for electrophoresis was an explanation. However, upon probing the same membrane with anti-HLA-DR antibody, it was clear that there was no lack of protein run on the gel! This result was quite striking because the general belief is that eIF-4E is an essential rate-limiting translation initiation factor. Interestingly, there was an additional smaller band recognized by the anti-HLA-DR antibody, raising the possibility of translation initiation on HLA-DR mRNA from a cryptic initation site. The undetectable expression of initiation factors in one case of diffuse large B cell lymphoma (Figure 6 ) could be explained by mutations in the motifs of eIF-4E and eIF-2a recognized by corresponding monoclonal antibodies used in our studies. However, other possibilities will be considered as well (discussed below).
Leukemias
During the last two decades many genetic alterations have been discovered that have been shown to play a role in the development of leukemias. The most common genetic abnormalities include aberrant expression of the Bcr-Abl tyrosine kinase (fusion product of a bcr/abl translocation) seen in all cases of chronic myelogenous leukemia (CML), in 20-40% of adult acute lymphoblastic leukemia (ALL; Heim and Mitelman, 1995, pp. 180-236; Harrison, 2001) , in 5% of pediatric ALL (Heim and Mitelman, 1995, pp. 180-236) and 3% of adult acute myelogenous leukemia, AML (Heim and Mitelman, 1995b, pp. 69-139) . Other common genetic alterations include activation of FLT3 tyrosine kinase in up to 31% of AML (either due to internal tandem duplication or activation loop mutations), and activation of Ras in 25-44% of AML and myelodysplastic syndrome cases (Kelly and Gilliland, 2002) . The downstream mediators of activated Abl and FLT3 include the STAT5, PI3K/AKT, Ras/MAPK, and NF-kB pathways (Kelly and Gilliland, 2002) . Importantly, activation of these signal transduction pathways in nonmyeloid cells (mostly fibroblasts and lymphocytes) has been shown to activate the translational machinery, see Figure 2 . Activation and translocation of NF-kB into the nucleus leads to induction of many genes (including c-myc) involved in mitogenesis and cell survival (Kessler et al., Figure 6 Western blot analysis of eIF-4E and eIF-2a in the lysates from lymph nodes effaced by lymphomas. The lymphoma-effaced lymph nodes virtually represent a dense three-dimensional homogenous suspension of lymphoma cells. There are very few other cells (almost no stromal component). Thus the population is nearly 100% pure and the results are not compounded by admixed cellular and stromal components. As shown, the top panel demonstrates eIF-4E expression in one case of small lymphocytic lymphoma (SLL), Burkitt lymphoma (Burkitt), and two cases of diffuse large B cell lymphoma (LBCL). Note the complete absence of detectable eIF-4E in one of the LBCL cases. The same membrane probed with an anti-HLA-DR (DR) antibody shows that the HLA-DR protein is present in all cases (an additional smaller-size band is seen in the lane lacking eIF-4E expression). Note that eIF-4E detected again in three other lanes (which demonstrated eIF-4E before) after probing for HLA-DR since the membrane was not stripped after first probing with anti-eIF-4E antibody (ECL was used for detection; the methodology and monoclonal antibodies used are described in Wang et al., 1999) . Also note an interesting co-incidence: a lymphoma with undetectable eIF-4E also demonstrates undetectable eIF-2a. There must be something qualitatively aberrant regarding the protein synthesizing machinery in this lymphoma, which killed a patient within a few months after diagnosis. No cells could be obtained to find out what alterations in the translational machinery were present in this lymphoma 1992; Romashkova and Makarov, 1999) . Thus, NF-kB activation is an additional pathway inducing c-myc expression in response to activation of Ras (Kerkhoff et al., 1998) and Abl (Cleveland et al., 1989) . Noteworthy, the c-myc gene is rarely altered in human leukemias (Nesbit et al., 1999) . However, as outlined above, the frequent genetic alterations present in human leukemias activate downstream pathways inducing c-myc expression. Our preliminary results confirm that c-myc activates expression of eIF-4E in human B lymphoblastoid cells (Rosenwald, unpublished results) . Although, based on a discussion above, it is likely that eIF-4E and other components of the translational machinery are downstream targets of various signal transduction pathways activated in leukemic cells, the role of translational alterations in human leukemogenesis is almost totally unknown and determination of the effects of genetic abnormalities on translational machinery awaits extensive studies. Importantly, it has been shown recently that the BCR-ABL kinase activates phosphorylation of ribosomal protein S6 and 4E-BP1 via the mTOR/rapamycin-dependent pathway in CML cells (Ly et al., 2003) .
Another example is acute promyelocytic leukemia, a neoplasm in which eIF-4E regulation appears to play a role (reviewed by Strudwick and Borden, 2002) . The key event in the development of this leukemia is the formation of a PML/RARa fusion protein as a result of a 15;17 translocation (Heim and Mitelman, 1995b, pp. 69-139) . This fusion protein disrupts normal functioning of a PML protein in the nucleus. Since a portion of eIF-4E is localized in the nucleus (Lejbkowicz et al., 1992) and is involved in the control of nucleocytoplasmic transport of some mRNA species, for example, cyclin D1 (Rosenwald et al., 1995; Rousseau et al., 1996b) , the authors examined the possibility that PML interacts with eIF-4E and its functional significance. It has been shown that normal PML protein binds eIF-4E and decreases eIF-4E binding to the cap structure (Strudwick and Borden, 2002) . Furthermore, when expressed in murine embryo fibroblasts, PML abrogates both upregulation of eIF-4E-mediated nucleo-cytoplasmic transport of cyclin D1 mRNA and eIF-4E-induced formation of transformed foci in an anchorage-independent growth assay (Cohen et al., 2001) . Although, a fibroblast model was used for these functional studies, the results suggest that disruption of normal PML function in the nucleus by a PML/RARa fusion protein in promyelocytic leukemia would lead to an increase in the functionally active eIF-4E and contribute to the neoplastic state. Furthermore, it has been recently discovered that the homeodomain protein, PRH, which is expressed in myeloid cells and some other nonhematopoietic tissues, co-localizes with eIF-4E in the nucleus (Topisirovic et al., 2003) . Similarly to PML, PRH suppresses the eIF-4E-mediated nucleo-cytoplasmic transport of cyclin D1 mRNA, thus preventing increase in cyclin D1 protein, and inhibits eIF-4E-induced transformation of NIH3T3 cells. Strikingly, the PRH mutant, which is unable to localize to the nucleus, still binds eIF-4E (in the cytoplasm), but cannot suppress the effect of eIF-4E on both cyclin D1 transport and transformation (Topisirovic et al., 2003) . These findings imply that increased eIF-4E activity in the nucleus may be essential for its transforming effects at least in some cell types. In this regard, it is appropriate to emphasize that nuclear localization of other translational components has been reported (reviewed in Strudwick and Borden, 2002) . Furthermore, it has been recently documented that significant protein synthetic activity actually takes place in the nucleus at the actively transcribed loci (Iborra et al., 2001; Iborra and Cook, 2002) . Although, it has been hypothesized that this translation serves a proof-reading purpose to assure appropriate placement of initiation and termination codons (based on observation that transcripts containing inappropriate termination codons accumulate close to transcription sites), it is equally possible that active translation in the nucleus serves the purpose of protein synthesis (those possibilities are not mutually exclusive). It is possible that a large portion of protein synthesis takes place in the nuclei of certain types of neoplastic cells, particularly those with very scant cytoplasm. For example, neoplastic cells of ALL frequently have very little or virtually no morphologically detectable cytoplasm, suggesting that nuclear protein synthesis may constitute a major portion of total protein synthesis in ALL cells (Figure 7 ). It would be very interesting to strip those nuclei from the scant cytoplasm and use 14 C-labeled amino-acid mixture to determine the rate of nuclear protein synthesis in ALL cells. Furthermore, it would be important to determine whether quantitative and/or qualitative alterations in the mechanism of translation are present.
In order to initiate the study on the role of eIF-4E and eIF-2a in human leukemogenesis we have analysed several cases of AML and ALL. Two cases of AML and two cases of ALL are shown in the Figure 8 . The two AML cases demonstrate marked upregulation of eIF-4E expression as compared to most myeloid cells in the normal bone marrow (eIF-2a is also upregulated in AML, not shown). However, in two cases of ALL the expression of both eIF-4E and eIF-2a was undetectable in most of the cells of leukemic infiltrate (note Studies are in progress to determine the mechanisms responsible for increased eIF-4E and eIF-2a in AML and to find out why these translation initiation factors are undetectable at least in some ALL cases (see discussion below).
What are the possible explanations for the lack of increase and undetectability of translation initiation factors?
In the 1990s, based on results in cultured cells, a number of investigators believed that genetic changes during initiation and progression of neoplasms lead to oncoprotein-induced increases in the expression and function of translation factors and other components of translational machinery (Rhoads, 1991; Rosenwald, 1996a, b; Larminie et al., 1998) . It was hypothesized that the gradual accumulation of oncogene abnormalities and loss of tumor suppressor functions leads to progressive quantitative increases in the function of translation factors and other components of translational machinery, thus facilitating tumor initiation and progression (Rosenwald, 1996a, b) . However, the recurrent theme that crystallizes as a result of some studies in the biopsies of human tumors discussed above is a lack of increase or even total undetectability of translation initiation factors eIF-4E and eIF-2a in some human neoplasms. I would like to offer some possible explanations of this phenomenon. (a) The monoclonal antibodies for eIF-4E and eIF-2a do not recognize the mutated forms of these initiation factors. Although, we do not have results yet to support or refute this possibility, I do not favor this explanation because one has to assume that the same motif is mutated in all tumors that have undetectable levels of these factors. Furthermore, since there are two alleles that can contribute to the gene expression, we have to assume that both alleles are identically mutated. (b) There may be alternative mechanisms for translation initiation operating in human neoplasms, which depend on neither eIF-4E nor eIF-2a.
eIF-4E
One possibility may be that there is another protein(s), either normal or abnormal, expressed in tumor cells that allows bypassing the requirement for eIF-4E. It should be mentioned that second human eIF-4E gene has been identified and shown to be expressed (Gao et al., 1998) . The protein product of this gene differs from originally cloned eIF-4E in only two amino acids, and it is unclear if the antibody we used recognizes this product or not.
Another possibility may be that alternative pathway(s) of protein synthesis do not rely on eIF-4E protein at all, but depend on qualitative alterations in translational machinery that completely or partially bypass eIF-4E-mediated transfer of mRNA to the ribosome. It should be noted in this regard that an increase in an eIF-4E inhibitor, 4E-BP1, has been detected in Figure 8 Expression of eIF-4E and eIF-2a in acute leukemias. In normal bone marrow (top left) megakaryocytes and occasional precursor cells (indicated by arrows) demonstrate expression of eIF-4E (eIF-2a is similarly expressed, data not shown). In the two cases of AML (M2 and M7 type, top middle and top right, respectively; M2 leukemia has characteristic 8;21 chromosomal translocation, M7 is a myelogenous leukemia originating from early megakaryocyte precursors), the expression of eIF-4E (and eIF-2a, which is not shown) is high. However, in two ALL cases (bottom left and middle) the expression of eIF-4E is not detectable or very weak in neoplastic cells, but is seen in megakaryocytes (indicated by arrow, bottom left). Expression of eIF-2a is also undetectable or very weak in ALL cells (bottom right), but is clearly seen in the blood vessel (indicated by an arrow, bottom right). The methodology for IHC analysis in bone marrow biopsies is described in Rosenwald et al. (2001b) gastrointestinal cancers when compared to normal tissues . One interpretation of these findings is that as transformation progresses a compensatory feedback mechanism is undertaking a futile attempt to inhibit translation that no longer depends as much on eIF-4E. With regard to a possible mechanism of eIF-4E-independent initiation of protein synthesis, one hypothesis may be that mRNA is delivered to a ribosome through its 3 0 end (polyA tail) in certain types of cancer. This hypothesis is consistent with the findings describing an essential feasibility of translation initiation by a mechanism(s) operating through mRNA 3 0 end (Preiss and Hentze, 1998) . Such a mechanism could involve the interaction of polyA-binding protein (PABP) with eIF-4G (eIF-4G interaction with PABP is well established; Mathews et al., 2000) , and a transfer of an mRNA to the ribosome mediated by eIF-4G interaction with eIF-3 (Mathews et al., 2000) .
eIF-2a
As discussed early in this review, this subunit of eIF-2 complex plays a regulatory role. When the a subunit is phosphorylated by PKR, the eIF-2-GDP complex blocks GDP/GTP recycling on eIF-2 by sequestering the recycling factor eIF-2B, which leads to inhibition of translation. One hypothesis may be that during tumor progression, in some instances, cells are selected to synthesize protein and proliferate without eIF-2a altogether in order to prevent downregulation of protein synthesis by PKR. Importantly, it has been shown in yeasts that deletion of eIF-2a can be compensated by cooverexpression of eIF-2b, eIF-2g and initiator methionyl-tRNA Erickson et al., 2001) . Most importantly, the eIF-2 complex composed of eIF2b and eIF-2g does not need eIF-2B for GDP/GTP recycling, and therefore cannot be inhibited as a result of a subunit phosphorylation (Erickson et al., 2001; Nika et al., 2001) . Thus, if only a portion of functional eIF-2 complex in a tumor cell is composed of only b and g subunits, then translation can occur despite the phosphorylation of eIF-2a by PKR. Independence of eIF-2 function from eIF-2a phosphorylation may explain the findings that expression and activity of PKR (p68) is frequently increased in gastrointestinal neoplasms (Singh et al., 1995; Lobo et al., 2000; Kim et al., 2002) and melanomas (Kim et al., 2002) . This increase in PKR may be interpreted as a futile attempt of a feedback mechanism to shut down translation.
It is possible that quantitative increases in the components of translational machinery play a role in the initiation of neoplastic transformation and early progression to malignant phenotype, while qualitative alterations in the mechanisms of translation play an essential role in progression to more aggressive phenotype (for example, in colon cancer progression sequence). This does not exclude the possibility that qualitative alterations are present at the initiation of transformation in other neoplasms (for example, in ALL cases that show no increase in both eIF-4E and eIF-2a).
The undetectability of translation initiation factors eIF-4E and eIF-2a in some neoplasms provided indirect clues to possible existence of qualitatively different mechanisms of translation. However, the alternative mechanisms may be at least partially responsible for the total protein synthesis in the tumors that did not loose or even upregulated the expression of eIF-4E and eIF-2a. Identifying those alternative mechanisms may become a basis for selective drug design leading to a more effective and safer therapy (discussed in the next section).
Translational machinery as a target for tumor therapy
Two recent reviews discussed possibilities of targeting components of translational machinery as a strategy for therapy (Caraglia et al., 2000; Meric and Hunt, 2002) . However, one essential problem that we have to consider when we attempt to design a therapeutic agent is its selectivity. How can we inhibit certain function in cancer cells without inhibiting the same in normal cells? It will be very difficult to inhibit a specific component of translational machinery in tumors without damaging normal cells that rely on the same component for their protein synthesis. How can specificity be achieved? One general approach is to use a delivery system that directs a toxin with certain degree of selectivity. An example of this approach is the use of toxin-coupled anti-CD20 antibody (e.g. Rituximab) that recognizes B cells and kills both CD20-positive lymphoma cells and normal B-lymphocytes (Abou-Jawde et al., 2003) . The normal B-lymphocytes recover after the treatment due to differentiation of CD20-negative precursor cells into mature B-cells. This therapy proved to be quite effective. Unfortunately, the situation, where a surface marker allows high degree of selectivity for targeting neoplastic cells without damaging many types of normal cells, is not common. Another general strategy is to identify selective targets inside cancer cells, for example, the BCR-ABL tyrosine kinase (a product of bcr-abl translocation present in all CML cases, frequently in ALL, and sometimes in AML cases). This translocation creates a fusion protein that is not present in normal human cells. Therefore, it was chosen as a promising selective target. Drugs have been designed, some proved promising in preclinical trials. The clinical trials are in progress and results are beginning to be analysed. The clinical trial data show that treatment with this drug markedly reduces proliferation of leukemic cells and relatively quickly reverses bone marrow morphology to normal (Hughes et al., 2003; Frater et al., 2003) . Also, treatment with a Bcr-Abl inhibitor appears to improve survival of patients with CML (Marin et al., 2003) . However, relapses are not uncommon and are explained by mutations in the drug target that make BCR-ABL kinase insensitive to the drug, or by activation of other signal transduction pathways complementing the BCR-ABL kinase and making proliferation of leukemic cells independent of BCR-ABL (Donato et al., 2003; Frater et al., 2003; Hochhaus, 2003) . While reliable evaluation of outcomes in patients treated with BCR-ABL inhibitors will not be ready for a few years, the problem of targeting one abnormal element of a signal transduction pathway emerges. While permitting selective targeting of neoplastic cells during treatment, the therapy fails not infrequently due to outgrowth of neoplastic cells that find a way to keep the same transduction pathway active or acquire mutations that activate parallel pathways. The framework for this concept was put forward by Rozengurt (1986) , who classified pathways leading to cell proliferation into regulatory signals and obligatory events. The regulatory signals fall into a universe of signal transduction pathways, while obligatory events are actually unique executive mechanisms, for example, DNA replication (translation may also be viewed as an executive mechanism). Importantly, regulatory signals form chains of parallel (and frequently cross-talking) pathways leading to the same obligatory events (executive mechanism). Therefore, regulatory chains can substitute for each other. Rozengurt suggested that targeting abnormal regulatory signals allows selectivity, and therefore may be a reasonable strategy for designing therapeutics. However, genomes of cancer cells are undergoing mutations, and under selective pressure the cells that develop a bypass of a targeted pathway would quickly outgrow. Therefore, in my opinion, targeting of signal transduction pathways may not be a solution as compensatory mutations in parallel or targeted pathways are likely to cause resistance. A combination of drugs targeting abnormally activated signal transduction pathway and one of the key executive mechanisms activated by that signal transduction pathway may be a more effective approach. Next question is: can executive mechanisms be selectively targeted? The logical answer is: unlikely, unless in cancer cells these executive mechanisms are qualitatively different from those in normal cells of the body. Note that the success of antibacterial therapy was only possible due to discovery of antibiotics that inhibited key executive mechanisms in bacteria because they target components present only in microbes or molecules that are qualitatively different from ones with similar function in eukaryotic cells. Examples are the antibiotics inhibiting protein synthesis in bacteria, but not affecting significantly the same in human cells (streptomycin, tetracycline). I have presented above some indirect clues indicating that qualitative alterations in the mechanisms of protein synthesis in cancer cells may exist and are worth searching for. For example, if qualitative alterations in the translational machinery that allow bypassing the requirement for eIF-4E are identified, those alterations may become selective targets for small molecule compounds. Another imperative is to determine whether the eIF-2-GTPiMet-tRNA complex active in tumor cells may include only b and g subunits of eIF-2, because such a complex would have a three-dimensional structure differing from the usual a, b and g-containing complex operating in normal cells, thus permitting selective drug design. In my opinion, by analogy with bacteria, the translational machinery may serve as a selective target if qualitative alterations in its components are identified in cancer cells.
Summary
A long-established association between increased translation rates, proliferation, and neoplastic transformation is the subject of newly aroused interest beginning in 1990, when it was discovered that overexpression of translation initiation factor eIF-4E results in cellular transformation (see review by Nahum Sonenberg, in this issue). Importantly, it has been shown that all major growth signal-transduction pathways lead to the regulation of translation (in addition to generally well-accepted regulation of transcription). Furthermore, it has been demonstrated that components of the translational machinery are targets of positive or negative regulation by major oncogenes and tumor suppressors, respectively. Importantly, major components of translational machinery are frequently, but not always, upregulated in human neoplasms. The lack of detectable expression of some key translational components in certain human tumors raises the possibility that qualitatively altered mechanisms of protein synthesis may operate in neoplastic cells. The increased expression of translation factors in tumors, particularly in highly aggressive ones, does not mean that alternative (qualitatively different) mechanisms are not in place. Identification of those qualitatively altered mechanisms may lead to a design of small molecules inhibiting protein synthesis in cancer cells without deleterious effect on normal cells. Intensive studies in this direction are necessary. 
